
|Articles|February 1, 2014
A Biomarker Development Trial of Satraplatin in Patients With mCRPC
Author(s)William K. Oh, MD
William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.
Advertisement
Clinical Pearls
William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer (mCRPC).
- Satraplatin is a next-generation chemotherapy drug that will not move forward in development
- It is known that there is a subset of patients with advanced CRPC that respond to platinum chemotherapy
- Blood- and tissue-based biomarkers are in development to predict the subset of patients that will respond
<<<
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















